Alto Neuroscience (NYSE:ANRO) COO Jr. Michael Conick Hanley Sells 2,896 Shares of Company Stock

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Michael Hanley sold 2,896 shares of the stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $26.48, for a total value of $76,686.08. Following the transaction, the chief operating officer directly owned 17,729 shares in the company, valued at approximately $469,463.92. This represents a 14.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jr. Michael Conick Hanley also recently made the following trade(s):

  • On Monday, November 16th, Michael Hanley sold 70,000 shares of Alto Neuroscience stock. The stock was sold at an average price of $27.68, for a total transaction of $1,937,600.00.
  • On Tuesday, November 17th, Michael Hanley sold 2,104 shares of Alto Neuroscience stock. The stock was sold at an average price of $26.82, for a total value of $56,429.28.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $25.77 on Thursday. Alto Neuroscience, Inc. has a 12 month low of $12.51 and a 12 month high of $37.48. The stock has a 50 day moving average of $25.83 and a 200-day moving average of $24.79. The company has a current ratio of 18.12, a quick ratio of 18.12 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13. Research analysts predict that Alto Neuroscience, Inc. will post -2.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ANRO shares. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research report on Thursday, November 12th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Wedbush raised their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, BTIG Research reiterated a “buy” rating and set a $37.00 target price on shares of Alto Neuroscience in a report on Wednesday, November 11th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.88.

View Our Latest Analysis on ANRO

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new position in Alto Neuroscience in the 2nd quarter worth $2,014,000. AWM Investment Company Inc. acquired a new stake in shares of Alto Neuroscience in the 2nd quarter valued at about $2,111,000. Jennison Associates LLC acquired a new stake in shares of Alto Neuroscience in the 1st quarter valued at about $8,687,000. Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after purchasing an additional 225,500 shares during the period. Finally, Orbimed Advisors LLC lifted its holdings in shares of Alto Neuroscience by 34.0% in the first quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock valued at $3,765,000 after purchasing an additional 42,500 shares in the last quarter.

Top Alto Neuroscience Stories

Investors following ANRO have been watching these stories:

  • Positive Sentiment: Alto reported a quarterly loss of $0.54 per share, narrower than the $0.67 loss analysts expected. That earnings beat may offer some support, though the company’s loss widened compared with the prior-year period. Alto Neuroscience reports wider quarterly loss and valuation analysis
  • Neutral Sentiment: A recent analysis questioned whether ANRO’s premium valuation is justified. This highlights valuation risk but does not provide a new company-specific catalyst. Alto Neuroscience valuation analysis
  • Negative Sentiment: COO Jr. Michael Conick Hanley disclosed selling shares, including a 70,000-share transaction and smaller sales. The reported reduction in his holdings could concern investors, although insider sales alone do not establish the company’s outlook. SEC Form 4 filing

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Featured Stories

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.